Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and ...

The EMA has approved Cullinan Therapeutics’ clinical trial application for CLN-978, a drug intended to treat rheumatoid ...

Cullinan Therapeutics (CGEM) announced that the European Medicines Agency, EMA, approved the Company’s Clinical Trial Application, CTA, for ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long awaited new treatment for early ...

EMA orphan drug designation is awarded to drugs intended to treat rare diseases that are life-threatening or chronically debilitatingPreeclampsia, a serious obstetric complication, is a leading cause ...

Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

The pharmaceutical industry faces environmental challenges. Green chemistry offers sustainable solutions to reduce waste and enhance drug discovery processes.

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the ...

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11 ...